Skip to main content

Table 1 Baseline demographic and disease characteristics

From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Demographic or disease characteristic

Number of subjects (N = 48)

Sex, n (%)

 

 Female

21 (44)

 Male

27 (56)

Race, n (%)

 

 White

33 (69)

 Nonwhite

15 (31)

  Asian

1 (2)

  Black or African American

13 (27)

  Multiracial

1 (2)

Age, years

 

 Mean (standard deviation)

61.6 (11.2)

 Median

62

 Range

39–81

Age, n (%)

 

 18–64 years

30 (63)

 ≥65 years

18 (38)

ECOG performance status, n (%)

 

 0

12 (25)

 1

31 (65)

 2

5 (10)

Prior chemotherapy regimens, n (%)

 

 ≤2

16 (33)

 3–5

23 (48)

 ≥6

9 (19)

Cancer type, n

 

 Colorectal

15

 NSCLC

5

 Ovarian

4

 Breast, melanoma

3 each

 Prostate, cholangiocarcinoma, adenoid cystic, sarcoma, pancreatic, neuroendocrine

2 each

 Esophageal, gastric, gastrointestinal stromal tumor, hepatocellular, pseudomyxoma peritonei, vulvar

1 each